Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Viralym-B for BK Virus Infections Post-Transplant
NCT02313844Phase 1Withdrawn
- Sponsor
- AlloVir
- Start
- Mar 2018
- Primary completion
- Jun 2019
- Modality
- Native Immune Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Viralym-B in BK virus infection, sponsored by AlloVir. Primary endpoint: Assessment of patients with adverse events after Viralym-B infusion at 42 days. Planned start Mar 2018; status: withdrawn.
02
Drugs
Viralym-B
03
Conditions
BK virus infection
Beyond the preview
Go deeper on NCT02313844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02313844.